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Abstract 
The use of antimicrobials in animal feed has come under increasing scrutiny from the 
public and regulatory agencies. Direct-fed microbials (DFM) are considered valuable alternatives 
to antimicrobials in food animal nutrition. DFM are products containing live (viable 
microorganisms). Studies in Europe have reported antimicrobial resistance (AMR) in organisms 
used in DFM. This is of serious concern because of the potential for transferring resistance to 
pathogenic bacteria in the gut. The aim of the present study is to characterize phenotypic and 
genotypic AMR profiles for 20 different antimicrobials in bacterial strains isolated from 10 
commercially available DFM used in. Two antimicrobial susceptibility testing methods, disc 
diffusion and broth micro-dilution based assay were performed. Enterococcus faecium isolates 
showed resistance towards metronidazole (n=9/9) with a MIC of > 32 µg/mL, erythromycin 
(n=5/9) with a MIC of ≥ 8 µg/mL, ciprofloxacin (n=2/9) with a MIC ≥ 4 μg/mL, ceftriaxone 
(n=6/9) with a MIC ≥ 0.25 μg/mL, rifampin (n=8/9) with a MIC of > 4 µg/mL, 
trimethoprim/sulfamethoxazole (n=4/9) with a MIC ≥ 1 μg/mL and clindamycin (n=5/9) with a 
MIC of > 0.5 µg/mL. A Propionibacterium freudenreichii isolate showed resistance towards 
kanamycin with a MIC of > 64 µg/mL. The same strain also had a MIC of 16 µg/mL for 
levofloxacin. Two Lactobacillus acidophilus were resistant to vancomycin (n=2/6) with a MIC ≥ 
32 μg/mL.  All the Lactobacillus species including L. acidophilus (n=6), L. casei (n=4) and L. 
plantarum (n=2) were resistant to metronidazole, MIC > 32 µg/mL.  Two strains of Bacillus 
subtilis showed resistance to clindamycin, with an MIC of 4 µg/mL and erythromycin with an 
MIC of > 8 µg/mL, and one strain had no zone of inhibition for metronidazole (MIC > 32 
µg/mL). Microarray analysis revealed resistance genes in E. faecium strains of 3 different DFM, 
including aminoglycoside resistance genes, ant(4’)-Ia, erythromycin resistance genes, ere(A2) 
  
and ermB, tetracycline resistance genes, tet39, tet31, tetK and tetC, and beta-lactam resistance 
gene, pbp5. Conjugation with filter mating showed erythromycin resistance gene transfer, msrC 
gene, from donor strains to a recipient strain (E. faecium 45-24). These studies show that AMR is 
prevalent among bacterial strains used as DFM in the cattle industry in the U.S., justifying 
further characterization, detection and observation of transferable antibiotic resistance between 
the same genus.  
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Preface 
 
Reason is the natural order of truth; but imagination is the organ of meaning. 
- C. S. Lewis 
 
 
 
 
 
 
1 
Introduction Chapter 1 - 
Antibiotics and Antimicrobial Resistance 
Antimicrobial agents, which include antibiotics, have long been used in veterinary and 
human medicine, including treating infectious disease in patients, working effectively to 
decrease illness and death since the 1940s (4, 26). According to the Centers for Disease Control 
and Prevention (CDC) (5), the most important factor that contributes to antibiotics resistance 
globally is the unnecessary use, overuse, and misuse of antibiotics, including providing incorrect 
doses. Overuse of antibiotics has also caused selective pressure, which inhibits bacteria that are 
susceptible to these antibiotics, thereby making additional resources available for resistant 
bacterial populations (2, 26). With antibiotics being used in such manner, antimicrobial 
resistance (AMR) is becoming a serious issue, continuing to negatively impact globally and in 
U.S. healthcare. Centers for Disease Control and Prevention (CDC) (5) define antimicrobial 
resistance as the “ability of microbes to resist the effects of drugs, where the germs are not killed 
and their growth is not stopped”. In the U.S., at least 23,000 people die annually from infections 
caused by AMR bacteria and approximately 2.3 million people are infected with microbes that 
are resistant to antibiotics (4). Use of antibiotics is influenced by knowledge, prescription choice, 
patient behavior, economics and health system (25). 
Antibiotics have long been used in food animals for treatment, prevention and control of 
infectious diseases, and growth promotion for the purpose of improving feed production and 
utilization (19). However, usage of antibiotics and the accompanying rise of resistant bacteria in 
food-producing animals have become a serious concern since these animals act as reservoirs for 
pathogens with the potential to transfer resistance to other pathogenic and opportunistic bacteria 
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(4, 5). Microbes allow mutations in their genes or exchange resistant traits between each other 
contribute to the natural phenomenon of the evolution of resistant strains (31).  
The development of resistant bacteria in food products and in production animals have 
been connected to resistant strains causing human food-borne infections, resulting from 
antibiotics used as antimicrobial growth promoters (AGP) (25). Suspicious usage of AGP has 
caused some countries within the European Union to act on this new research, such as Sweden in 
1986, Denmark in 1998-1999 and Norway in 1995 (25). However, while there have been 
documentations on foodborne pathogens with multiple resistances, the vast majority of most 
bacteria on meat are susceptible to most antibiotics.  Antibiotics used in human medicine have 
been recommended to be banned for use as growth promotants in animals (19, 20). These 
recommendations took effect in European countries and Canada, with the use of growth 
promoters being banned throughout Europe in 2006 (19, 20, 32). This resulted in more than 50% 
reduction in antibiotics usage, specifically macrolides) in pigs from 1992 to 2008, without any 
decrease in productivity (32). The United States still continued the usage of these growth 
promoters. Use of antibiotics for growth enhancement in livestock has been said to be the most 
controversial (19, 20). Other cases include more than 57% and 59% of dairy operations in the 
United States treating respiratory and diarrheal disorders with antibiotics in dairy cattle. More 
than 85% of operations use antibiotics like aminoglycosides, tetracycline and macrolides to treat 
mammary infections in mature cows (20).  
In addition to the decline of development and research of newer antibiotics to curb this 
imbalance, there is a lack of regulation of antibiotic use in agriculture especially in food animals, 
a lack of surveillance and control, and inadequate coordination efforts (4). AMR calls for 
immediate attention due to the fact that resistant microbes do not respond to the typical 
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treatment. Failure of standardized medical treatments will result in persistent illness, higher risk 
of death along with increasing health care cost (31). Other negative effects were observed in 
poultry, including colonization of chickens with tetracycline-resistant as well as other drug-
resistant Escherichia coli strains. Enterococcus species, on the other hand, were found to harbor 
various tetracycline resistance genes in chicken regardless of being exposed to the drug or not 
(19, 20). In short, pathogenic species which are mostly Gram-negatives, pose an immediate 
threat to the human/animal health as it is difficult to eradicate those carrying AMR determinants. 
Gram-positives with AMR consisted mostly of non-pathogenic or opportunistic pathogens (8).  
Transfer of resistance to humans through the food chain where livestock harbor 
foodborne pathogens such as Salmonella species, Campylobacter species and some strains of E. 
coli have been observed (20). One of the routes for transfer of resistant determinants in bacteria 
is close contact, which can occur between animals, people, animal products, feces and surface 
water (5).  This is a cause for concern since use of antibiotics in animals carrying these 
foodborne pathogens may contribute to selection for more resistant populations. Under selective 
pressure, these pathogens have an advantage that can help in their colonization, which can result 
in a higher pathogen load (20). There are also suggestions of antibiotic resistance selection in 
nonpathogenic microflora that could provide additional reservoir of resistance genes. There is the 
possibility of increased prevalence of resistance factors on integrons, transposons and plasmids 
since non-target enteric microflora are exposed to the same antibiotic regimens as the foodborne 
pathogens which are the highest profile risk (13). The outcome of this exposure in microflora 
includes the establishment of a resistance reservoir which can support transfer of resistance to 
pathogenic bacteria. (13).  
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Assessing any threat to public health from AMR in farm animals is crucial and levels of 
resistance must be determined in those populations. However, passive surveillance is relied on 
for national level reporting of AMR in farm animals. A complete ban on antimicrobials use in 
farm animals would cause serious repercussion on animal welfare, health, productivity and also 
food prices. Hence, negative effects of antibiotic restriction in animal agriculture might be at 
least partially offset by viable antibiotic alternatives (32). However, if any, few antimicrobial 
alternatives have demonstrated the same beneficial effect as antimicrobials on infectious 
bacterial disease in humans or animals.  
 
Intrinsic and Acquired Antimicrobial Resistance  
Antimicrobial resistance includes two categories, intrinsic and acquired. Intrinsic 
resistance is defined as when a particular strain possesses inherent properties that decreases its 
susceptibility to some antibiotics. In short, it is naturally resistant to certain actions of 
antimicrobials (10). The second category is acquired resistance where a strain which is originally 
susceptible to a certain antimicrobial becomes resistant (29). One pathway of acquired resistance 
is through mutation of the gene into a resistance gene, occurring during a bacterial replication. 
The rate of mutation is determined by bacterial genetics, population dynamics, cell physiology 
and environmental factors (21). Another method of acquired resistance involves resistance 
determinants being incorporated into the recipient bacterium from a donor bacterium via three 
forms of horizontal gene transfer, which are transduction, transformation and most importantly, 
conjugation (5). The transfer of DNA fragments during conjugation can vary from large to small 
chromosomes. The general procedure of a conjugation process is a contact between cells, 
formation of a mating pair and lastly, the transfer of a plasmid DNA through a pilus or a pore 
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forming a channel allowing for the plasmids to pass through (14). The spread of mobile genetic 
elements enables the transfer of resistance through autonomous self-replicating plasmids, 
transposons or gene casettes/integrons (5). Integrons have the potential as an important part of 
dissemination of multi-drug resistance (MDR) among bacterial strains. Class 1 integrons, one of 
the classes of the resistance integrons (RI) carrying gene cassettes that encode resistance to 
antibiotics and disinfectants, are most commonly found in bacteria associated with livestock 
(20). Transposons, on the other hand, are the most frequent mechanism that contributes to the 
spreading of AMR in bacteria. One such example is the conjugative transposon, Tn916, carrying 
the tetM gene and exhibiting a wide host range of Gram-positive and Gram-negative bacteria (8).  
Natural transformation also allows for the uptake of plasmid and chromosomal DNA 
from the environment, where bacterial cells take up free DNA and insert it into their genomes. 
Natural genetic transformation begins with donor cells releasing their DNA, after which it 
disperses and persists in the environment. The recipient cells then become competent for DNA 
uptake, followed by taking up the DNA. Through illegitimate or homologous recombination, the 
competent cells incorporate it into their genome, with the donor DNA genes expressed in the 
recipient cells (14).  
Another mechanism that facilitates transfer of virulence and antimicrobial resistance 
genes is transduction by bacteriophages. Bacteriophages are viruses that infect bacteria, 
including lytic and temperate phages. The transfer of antibiotic resistance or virulence genes by 
phage-mediated transduction has been reported in Enterococcus faecalis strains. Another study 
also demonstrated transfer of genes from staphylococci to enterococci via the same mechanism 
(9).  
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Direct-Fed Microbial 
Probiotics are “live microorganism which when administered in adequate amounts, 
confer health benefit on the host”.  The terms “probiotics” and “Direct-fed microbial” are used 
interchangeably. However, they are not similar (21). Direct-fed microbial (DFM) products is 
defined by the U.S. Food and Drug Administration as products that are purported to contain live 
(viable) microorganisms. FDA requires feed producers to utilize this term, instead of probiotic 
(16). However, based on consumer understanding, DFM products include live and non-living 
supplements enhancing bacterial growth as per feed producers. In the twentieth century, DFM 
products were first used in animal husbandry to reduce Salmonella causing intestinal 
colonization in chickens, to decrease diarrhea in cattle and pigs, increase milk production in 
cattle and feed utilization efficiency in pigs (3). 
 Benefits of using DFM include the influence of microorganisms on animal health and 
their productivity in terms of competitive exclusion of pathogenic bacteria, competition for 
mucosal attachment and nutrients, production of bacteriocins, acid fermentation lowering 
intestinal pH, and stimulation of the gut associated immune system. DFM products contain 
different genera and species, as well as different strains of the same species (30).  
 Functional and technological characteristics of each strain are the basis for selection of 
certain strain for inclusion in a DFM product. There are guidelines to be followed, which include 
identification methods specifications and assessment of safety characteristics of the strain. The 
strains should be safe in terms of antibiotic resistances in them (6).  Generally, probiotic bacteria 
should be able to adhere to the intestinal mucosa and behave antagonistically towards other 
pathogens (22).  
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About 20 microbial feed additives are allowed to be used in the European union (3) The 
most commonly used species include lactic-acid producing bacteria (LAB) that can convert 
fermentable carbohydrates into lactic acids, such as Lactobacillus, Enterococcus, Streptococcus 
and Pediococcus species (18, 21). Bacillus, Enterococcus and Lactobacillus species are more 
than likely to be efficient in poultry and pigs (3). This particular group has had a long history of 
safe usage in food production, leading it to acquire the GRAS (generally recognized as safe) 
status, which was designated by the Qualified Presumption of Safety (QPS) classification by the 
European Food Safety Authority (EFSA) and the US Food and Drug Administration (FDA) (8). 
The LAB group also has the ability to limit the activity of Salmonella in vitro by producing 
hydrogen peroxide in the presence of oxygen (21). It has also been shown that Lactobacillus 
acidophilus strain NP51, one of the strains in a DFM for cattle, reduced Escherichia coli 
O157:H7 fecal shedding in cattle (21). Other bacteria used in DFM include Bacillus and 
Bifidobacterium which are generally used in poultry, and yeasts such as Saccharomyces 
cerevisiae primarily used in dairy cattle. In the cattle industry, DFM has been used to improve 
milk production, growth performance and feed conversion efficiency, either mixed in the feed or 
administered to the animal in the form of an encapsulated bolus (20).   
Most DFM or probiotics are common members of the human intestinal tract. Since they 
are consumed in large amounts, the presence of antibiotic resistance determinants in their 
genome must be screened (13). It has been acknowledged that LAB plays a role as a reservoir of 
antibiotic resistance determinants with the potential to transmit this resistance to pathogenic 
species, posing a potential health risk which has been largely ignored in the past (8). There have 
been proposed theoretical risks that colonization with DFM/probiotics can have a negative 
impact on gastrointestinal physiology and function. Other risks include localized and generalized 
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immunologic effects. Among all, the most worrying concern is the potential for antibiotic 
transfer from the DFM to commensal or pathogenic bacteria in the gastrointestinal tract (27). 
 
Strains in DFM 
Lactobacillus 
The Lactobacillus genus, a Gram-positive bacterium, is used frequently in DFM. This 
genus is generally recognized as safe (GRAS) and can be traced back to having a long history of 
safe usage in dairy products and foods (13, 27). Some lactobacilli have been characterized as 
having intrinsic resistance, including a vancomycin-resistant phenotype reported in L. paracasei, 
L. salivarius and L. plantarum (13, 26). This genus is also generally more resistant to 
cephalosporins and has higher resistance to aminoglycosides such as kanamycin and gentamicin. 
However, it is susceptible to antibiotics like penicillin and other β-lactams, as well as to low 
concentrations of inhibitors targeting bacterial protein synthesis such as lincosamides, 
macrolides, chloramphenicol and tetracyclines (13). The lactobacilli have also been shown to be 
intrinsically resistant to aminoglycosides, glycopeptides and fluoroquinolones (18).  In L. 
acidophilus, L. fermentum and L. rhaminosus, there is a higher prevalence of phenotypic 
resistance to aminoglycoside due to amplicons of resistance genes that encode resistance for 
aminoglycosides, aph[3’]-III, aaadA, aadE, as well as tetracyclines, tetS (26). The Lactobacillus 
species is also intrinsically resistant to trimethoprim due to a dihydrofloate reductase (7).  
There are also several genes contributing towards atypical antibiotic resistance properties 
detected in lactobacilli such as the chloramphenicol acetyltransferases (cat genes), found in L. 
acidophilus, L. johnsonii, and L. delbrueckii subspecies bulgaricus. Other genes demonstrated in 
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lactobacilli, but not as often, include the aminoglycoside resistance genes, aph(3)-IIIa, aac(6 )-
aph(2) and ant(6) (8). 
There are also antibiotic resistance phenotypes in lactobacilli due to chromosomal 
mutations.  Recent studies have confirmed that erythromycin, ermB, and tetracycline, tetM, 
resistance genes in lactobacilli represent the most widespread resistance determinants (8). Other 
erythromycin resistance genes, including ermB, ermA, ermC and ermT, which are responsible 
for the macrolides, lincosamides, and streptogramins (MLS) resistance phenotype are present in 
a few of the lactobacilli species. Some of the erythromycin resistance genes, ermC, msrC, and 
tetracycline resistance genes, tetS, tetW, tetK, tetL and tetO, encode for ribosomal protection 
proteins (8, 13). 
 Tetracycline and erythromycin resistance were also detected in L. plantarum 5057, with 
claims of L. plantarum harboring ermB and msrA/B genes as well as tetM genes (26, 27). Other 
studies have demonstrated transfer of an introduced plasmid encoding erythromycin resistance, 
such as pAMβ1, from L. plantarum and L. reuteri to other Gram positive bacteria in vivo and in 
vitro (12).   
It is important to note there is evidence conjugation transfers from enterococci to 
lactobacilli in the animal gut. Transfer of resistance to lactobacilli, on the other hand, is not very 
common (27). 
 
Enterococcus 
Enterococci are one of the many inhabitants of the normal intestinal flora, and also an 
important nosocomial pathogen. One of the major concerns related to the Enterococci species 
includes a dramatic increase in the number of infections in the medical community, causing 
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infections like peritonitis, endocarditis and bacteremia (11). Enterococcus faecium and 
Enterococcus faecalis display a high prevalence in feces of healthy animals and are able to 
harbor resistance determinants (5). Among enterococci, there are many mechanisms of intrinsic 
and acquired resistance belonging to the major antibiotic classes of clinical use (11). In some 
cases, antimicrobial resistance does not add to the safety concern if intrinsic resistance 
mechanisms or mutations are the cause of the resistance phenotype among strains. However, if 
the resistance determinants or markers are carried on mobile genetic elements such as plasmids, 
transposons or integrons that constitute a reservoir of resistance, then there are causes for 
concern (13). 
In general, this genus demonstrates a low intrinsic resistance to β-lactam antibiotics such 
as ampicillin, penicillin and imipenem. Resistance towards β-lactam antibiotics implies low 
affinity of penicillin-binding proteins (PBPs). Genes encoding β-lactamases can be located either 
on the chromosome or plasmids and can contribute to high-level resistance (11). Higher levels of 
ampicillin resistance in the early studies were observed in Enterococcus hirae, achieved through 
increasing PBP5 expression levels. This case is similar to those in E. faecium. In clinical isolates 
however, the high level of resistance is rarely related to increasing PBP5 levels of expression. It 
is more common to presume mutations lower susceptibility to the β-lactam antibiotics, which 
have been identified in highly resistant clinical isolates within pbp5 genes. (23).  
Enterococci have also developed resistance towards aminoglycosides which include 
gentamicin, streptomycin and kanamycin. In general, this genus is intrinsically resistant towards 
low-level aminoglycosides due to low cellular permeability. However, they develop high level 
resistance due to mutations affecting the protein of the 30S ribosomal subunit as well as an 
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aminoglycoside-modifying enzyme that removes the synergistic bactericidal effect observed 
when an aminoglycoside is used in combination with a cell wall-active agent (6, 11).  
Another form of resistance is a 16S rRNA modification where the rRNA 
methyltransferase, EfmM uses S-adenosyl methionine as a methyl donor to methylate a specific 
residue on the 16S rRNA. High level resistance to aminoglycosides is also mediated by 
aminoglycoside-modifying enzymes including acetyltransferases (AACs), 
nucleotidyltransferases (ANTs) and phosphotransferases (APHs) (11). Some examples of 
clinically important resistance genes enzymes include the bifunctional gene aac(6′)-Ie-aph(2″)-Ia 
encoding the enzyme Aac(6′)-Ie-Aph(2″)-Ia, which helps the strain to be resistant to some 
aminoglycosides like kanamycin, tobramycin, amikacin, netilmicin and gentamicin (MIC ≥ 500 
µg/mL). It has been reported that E. faecium strains produce the aforementioned aminoglycoside 
acetyltransferase, Aac(6′)-Ii, which is chromosomally encoded. This enzyme eliminates the 
synergism between tobramycin, netilmicin, sisomicin and kanamycin aminoglycosides and cell 
wall-active antimicrobials. An aminoglycoside phosphotransferase, Aph(3′)-IIIa, encoded by the 
aph(3′)-IIIa gene confers a high-level resistance towards kanamycin and an aminoglycoside 
nucleotidyltransferase, Ant(4″)-Ia, encoded by the ant(4′)-Ia gene, confers resistance towards 
kanamycin, tobramycin and amikacin. There have been cases of the rise of new gentamicin 
resistance genes, aph(2″)-Ic and aph(2″)-Id, with the latter detected in vancomycin-resistant E. 
faecium as well. The prevalence of increasing aminoglycoside resistance genes among clinical 
enterococcal isolates, especially aac(6′)-Ie-aph(2″)-Ia, limits the choice of using 
aminoglycosides for synergistic combination therapy. A somewhat promising newer 
aminoglycoside is arbekacin, a derivative of dibekacin, used in Japan to treat methicillin and 
12 
gentamicin-resistant Staphylococcus aureus infections. There is a need for development of more 
potent but less toxic aminoglycosides to aid in combating enterococcal infections (6).  
Acquired resistance to glycopeptides such as vancomycin have also been observed and 
reported based on phenotypic and genotypic criteria (11). Enterococci which are vancomycin-
resistant are normally associated with nosocomial infections in the hospitals, and this type of 
resistance is transferable in vitro (22). Vancomycin resistance genes, vanA and vanB are the 
most prevalent with most van genes located in plasmids or transposons as well, facilitating their 
dissemination through horizontal gene transfer. The resistance gene vanA, encoding for D-ala-D-
lac ligase, is mostly transferred by Tn1546, a transposon of 10851bp related to Tn3. Unlike the 
vanA phenotype where it confers resistance to both vancomycin and teicoplanin, the vanB 
phenotype confers some resistance of variable degree to vancomycin but most of the strains are 
still sensitive to teicoplanin in vitro. It seems that most of the vanB-mediated resistance 
phenotype is acquired through horizontal dissemination of vanB2 genes through Tn916, a 
conjugative transposon (11).  
Macrolides such as erythromycin are also important, with it being the first choice to use 
in patients that are allergic to penicillin. Tylosin is another macrolide commonly used in pigs 
(11).  In European countries, erythromycin resistance ranged from 14 to 82% in E. faecium and 
86 to 94% in E. faecalis. However, a decrease in resistance to 46.6% was observed in Denmark 
in E. faecium and from about 90% to 28.1% in E. faecalis, when the usage of tylosin was 
reduced (15). Mechanisms of resistance include target modification by precise mutations and 
methylation of the 23S rRNA subunit which prevents binding of macrolides such as ermA, ermC 
and ermB. Other forms of resistance mechanism includes hydrolysis of the lactone ring of the 
antibiotic molecule, and efflux pumps removing antibiotic molecules from inside of the bacterial 
13 
cells are encoded by genes such as mefA, mefE, msrC, mreA and msrA. The more frequently 
occurring macrolide resistance determinants are the erm genes, like ermB, encoding for 
methyltransferase acting on specific residues of the 23S rRNA subunit and mostly located on 
plasmids (11, 15) The functionality of the enzyme then inhibits erythromycin binding by causing 
a N6-dimethylation of an adenine residue in the 23S rRNA subunit (11). This gene not only 
mediates resistance to erythromycin but confers resistance to other active macrolides used in 
human medicine (15). Modification of the ribosomal target causes cross resistance to macrolides 
or lincosamides, macrolides, ketolides and streptogramin A and B (MKS) or macrolides, 
lincosamides and streptogramin B (MLSB) (11). 
Enterococci have also developed resistance to lincosamide, more commonly described in 
E. faecium. This type of resistance is mediated by lincosamide nucleotidyl transferase, encoded 
by linB, catalyzing 3-(5’-adenylation) of both clindamycin and lincomicin. Another antibiotic 
combination, quinupristin-dalfopristin inhibits bacterial protein synthesis and is quite effective 
on E. faecium, while E. faecalis, is intrinsically resistant to this antibiotic. However, just like 
with other antibiotics, acquired resistance towards this antibiotic in E. faecium  is mediated by 
streptogramin acetyltransferase enzymes that acetylate streptogramin A such as VatB, VatE, 
VatG or VatD, hydrolases encoded by vgbA, or ATP-binding transporters encoded by vgaB. 
ABC transporter, encoded by the gene lsa, mediates streptogramin A and lincosamide resistance 
(11).  
There have been frequent cases of resistance of enterococci towards tetracycline. 
Tetracycline resistance is normally associated with the gene tetM, conferring ribosomal 
protection and associated with Tn916-type transposable elements found on both chromosomes 
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and conjugative plasmids. Other genes that also confer ribosomal protection include tetO and 
tetS. Genes encoding tetracycline export pumps include tetK and tetL (11).  
 Rifampicin resistance is also frequent in enterococci, arising from commensal microbiota 
exposure towards the antibiotic while treating other bacterial infections. The resistance is due to 
mutations in the RNA polymerase B subunit rpoB gene. Linezolid, belonging to the group 
oxazolidinones, also has a high antimicrobial activity towards Gram positive bacteria, with any 
resistance being due to mutations in the 23S ribosomal subunit. It has been shown that strains 
which are resistant to linezolid can also demonstrate co-resistance to other antibiotics like 
ampicillin, macrolides, fluoroquinolones, chloramphenicol, rifampicin, gentamicin, 
nitrofurantoin, trimethoprim/sulfamethoxazole and vancomycin. (11). 
 Enterococci have also shown increasing resistance towards quinolones. There have been 
cases reported where this resistance is due to mutations affecting the GyrA subunit of the DNA 
gyrase, as well as the ParC subunit of topoisomerase IV. The second quinolone resistance 
mechanism is mediated by the proteins of the Qnr family, functioning to protect the DNA gyrase 
and topoisomerase IV from the inhibition of quinolones. Multidrug-resistant efflux pumps like 
EmeA and EfrAB mediate the third mechanism of quinolone resistance (11). 
  Resistance towards heavy metals like copper is also on the rise, which can raise 
opportunities for cross selection of antibiotic resistance. The copper homeostasis was first 
described in copYZAB operon from Enterococcus hirae. There have also been reports of a 
transferable plasmid copper resistance gene, tcrB (transferable copper resistance homologous to 
copB), which encodes a putative protein that belongs to the CPx-type ATPase family of heavy 
metal transporters. This particular gene is genetically linked to genes that encode other 
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resistances like macrolides, ermB and glycopeptides, vanA, in plasmids that originate from pig 
isolates (11).  
Enterococcus species are a controversial species with questionable usage in DFM or 
probiotics due to its potential pathogenicity and resistance towards some of the most commonly 
used antibiotics (18).  
 
Bacillus 
The Bacillus species is commonly used in probiotic dietary supplements for humans and 
in animal feed additives, plant production products or vitamin/enzyme production to help 
encourage stimulation of the immune system. Some Bacillus species generally used include 
Bacillus subtilis, B. pumulis and B. clausii, with the latter commonly used to prevent infectious 
bacterial diarrhea. This genus, which is not part of the commensal microbiota, is rod-shaped, 
aerobic or facultative aerobic Gram-positive bacterium which forms endospores (1, 13). Despite 
its common usage, there is limited information concerning the antimicrobial susceptibility of 
Bacillus and also its potential for transfer of resistance genes. It has been demonstrated that the 
Bacillus species is resistant to antibiotics like erythromycin, lincomycin, streptomycin, 
chloramphenicol, tetracycline and penicillin. For instance, B. clausii and B. lincheniformis 
isolated from broiler breeds were resistant to both lincomycin and erythromycin. Another study 
also observed antibiotic resistance to tetracycline, rifampin, chloramphenicol and streptomycin in 
B. subtilis in a probiotic product, Enterogermina (Sanofi-Aventis) (1).  
For the Bacillus spp., erythromycin resistances genes conferred resistance through 
methylation of 23S rRNA macrolide binding sites. Some examples include B. subtilis, conferring 
ermD and ermI, B. clausii conferring erm34 and B. anthracis conferring ermJ (1). Macrolide-
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resistance genes and tetracycline resistance have also been observed in mobile elements like the 
plasmid-encoded ermC and in the plasmid-encoded tetL gene in B. subtilis. Another tetracycline 
resistance gene, tetM, contained in the conjugative transposon Tn5397 has also been found in the 
same species. It has been reported that tetK has also been identified in other Bacillus strains. 
Other reports detected the presence of cfr-like genes, encoding ribosome methyltransferases, in 
some Bacillus species. These genes encode resistance to antibiotics like oxazolidinones, 
lincosamides, pleuromutilins, streptogramin A and phenicols (13). 
Due to the limited information and data in regards to the Bacillus spp., validated 
breakpoints for the different species are needed (1).  
 
Propionibacterium 
Another strain used in DFM is the Propionibacterium genus in the Actinobacteria class 
of bacteria. This genus is a Gram-positive, catalase positive, non-spore forming, anaerobic or 
aerotolerant, non-motile pleomorphic and rod-shaped bacteria. Typically, the species within this 
genus are divided into either dairy or classical and cutaneous. Propionibacterium freudenreichii, 
used in the Bovamine direct-fed microbial, is a part of the classical propionibacteria isolated 
from the dairy and milk environment. Generally, propionibacteria are used to improve the shelf 
life of food products as their antimicrobial activity helps to decrease the spoilage of food and 
mold growth. Other benefits of this genus also include the stimulation of the immune system, 
limiting cancer progression and assisting in reducing mutagen-producing fecal enzyme activities. 
The mechanism for the latter effect involved is not well-defined. Another positive attribute of the 
propionibacteria is its ability to adapt and tolerate digestive stress in the human gut, persisting 
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temporarily for weeks in the gut. An interesting fact about Propionibacteria is that it is able to 
enhance the growth of Bifidobacteria by modulating the intestinal microbiota (6, 22).  
There are few published studies describing antibiotic susceptibility of propionibacteria, 
including breakpoints values (6). However, there are reports of moderate of susceptibility to 
tetracycline, chloramphenicol, erythromycin, bacitracin, ampicillin and vancomycin (22). 
Resistance to aminoglycosides like gentamicin, kanamycin and streptomycin is common for 
anaerobic bacteria since they do not have a cytochrome-mediated drug transport system (6).  
 
Bifidobacterium 
Bifidobacterium is one of the main phylogenetic groups of the human gut microbiota 
Some of the Bifidobacterium spp. used in DFM  include B. thermophilum, B. breve, B. bifidum 
and B. animalis. B. animalis subsp. lactis is frequently used in fermented dairy products. 
Although the presence of resistance genes in the Bifidobacterium species in the gut does not pose 
a direct threat due to the lack of infectivity, it is still harmful in the sense that it constitutes a 
reservoir where resistance genes can be transferred to pathogenic organisms (13). This genus is 
intrinsically resistant to mupirocin, inhibiting protein synthesis by competing with isoleucine as a 
substrate for isoleucyl-tRNA synthetase. Bifidobacterium’s resistance is due to synthesis of 
atypical isoleucyl-tRNA synthetase containing amino acid residues accountable for the high 
resistance of mupirocin. Bifidobacterium is also not susceptible to aminoglycosides in high 
concentrations due to the lack of cytochrome-mediated drug transport. However, this genus is 
generally inhibited by low concentrations of vancomycin, beta-lactams, rifampicin, macrolides, 
chloramphenicol and spectinomycin. It has been reported that streptomycin resistance is seen in 
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some Bifidobacterium strains such as B. breve and B. bifidum, suggesting there is chromosomal 
mutation on the rpsL gene for ribosomal protein (12).  
Even in Bifidobacterium, there is limited information in regards to antibiotic resistance 
determinants, with only data on tetracycline and macrolide antibiotics known. However, multi-
drug resistance (MDR) has been found in B. breve and B. longum where the transporters 
conferred resistance to erythromycin. As a part of the transposon Tn5432, ermX, a gene that 
encodes for a ribosomal protection protein, was found in B. animalis subsp. lactis and B. 
thermophilum. Tetracycline resistance genes, tetW, tetM, tet(O/W), tet(W/32/O) and tetO, have 
also been found in some strains of bifidobacteria, including B. animalis subsp. lactis, B. bifidum 
and B. thermophilum. There is a possibility that under suitable conditions, tetW resistance genes 
can be transferred, due to the gene being flanked by either gene coding for transposases or 
transposase target sequences. Therefore, enzymes catalyzing the movement of DNA fragments 
between several locations recognize specific target sequences. An example was found in B. 
longum, with a transposase located in the conserved upstream region of the gene as well as being 
flanked by flawed direct repeats. At low frequencies, there was transfer of the tetW gene 
between B. longum and B. adolescentis (13).  It can be concluded that there is potential for the 
transfer of antibiotic resistance genes between closely related bifidobacteria. 
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Antimicrobial Resistance in DFM strains Chapter 2 - 
For more than 60 years, use of antimicrobials in veterinary medicine and animal 
husbandry produced positive results in healthier and more productive farm animals. This ensured 
the health and welfare of animals and humans. However, antibiotic-resistant bacteria are 
increasing and causing infections. Contribution to emergence of resistance has been credited to 
the usage of antibiotics in farm animals, where reservoir of resistance is transmitted either 
indirectly or directly through food consumption to humans (6). 
Direct-fed microbial (DFM) are feed products containing only live or naturally occurring 
microorganisms and have been used over 20 years in the cattle industry (9). Commercially used 
as probiotic supplements and starter cultures, lactic acid bacteria (LAB) are one of the reservoirs 
for various antibiotic resistance genes, developing from overuse of tylosin, virginiamycin or 
lincomycin antibiotics as growth promoters. The most concerning mechanism for antimicrobial 
resistance transfer is conjugation, which contributes to the global spread of resistance through 
transposons and conjugative plasmids. This includes macrolide resistance transfer from food 
LAB to intra, inter-generic LAB as well as pathogens. One of the worrying LAB used as strains 
in DFM is the Enterococcus, which has been known to cause increasing frequency of nosocomial 
infections, especially in immunocompromised patients. This genus has the potential to acquire 
extrinsic resistance genes, such as erythromycin, vancomycin, tetracycline and chloramphenicol. 
Besides resistance genes, virulence factors such as enterococcal surface protein (ESP) and 
aggregation substance (AS) are also found in Enterococcus, giving rise to Enterococcus as an 
opportunistic pathogen. With these reports regarding enterococci, the safety of using this strain 
in DFM must be assured and its benefits analyzed (2). With the decreasing, limited and free 
usage of antimicrobials in livestock, there has been an urgent call for new interventions and 
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strategies to decrease the emergence and prevalence of antimicrobial-resistance bacteria in 
livestock. Resistant strains in DFM used in food systems and feed should be monitored and 
assessed by proposing guidelines, regulations, standards and criteria (17).  
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Materials and Methods 
Bacterial strains  
Twenty-six strains of various genera such as Enterococcus, Lactobacillus, 
Propionibacterium and Bacillus were isolated from ten DFM.  The numbers of strains isolated 
are shown in Table 2-1.  
 
Bacteria isolations  
One gram of each DFM was inoculated in 10 mL of peptone water (Thermo Fisher 
Scientific) or de Man Rogosa and Sharpe broth (MRS, Oxoid, Thermo Scientific) and incubated 
overnight aerobically at 37°C (Enterococcus and Bacillus species) or anaerobically 
(Lactobacillus species at 37°C and Propionibacterium freudenreichii at 30°C). The inoculum 
was plated on blood agar and incubated for 4-5 days at 30°C to isolate Propionibacterium 
freudenreichii. Different colonies were picked based on morphology and a positive catalase test 
indicated the presence of P. freudenreichii. For Bacillus strains, the same procedure was used but 
plated on Brain Heart Infusion (BHI) agar and incubated aerobically at 37°C for 16-18 hours. 
The catalase test result was also positive for Bacillus species. Enterococcus faecium was isolated 
and identified by plating the culture mix on a BHI agar and incubating it aerobically at 37°C for 
16-18 hours. Based on colony morphology, E. faecium was picked and Gram stained.  An esculin 
hydrolysis test was performed to further confirm E. faecium. For further identification, the strain 
was streaked on m-enterococcus agar (Becton Dickinson, BD) and dark pink colonies observed 
indicated the presence of E. faecium. All bacterial species were further confirmed using Matrix-
Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF). Lactobacillus casei and 
plantarum were isolated by plating the inoculum on MRS agar with 0.25% L-cysteine 
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hydrochloric acid (HCl) and incubated anaerobically for 24-48 hours at 37°C. Based on distinct 
morphologies, different colonies were Gram-stained to confirm that they were Lactobacillus 
species. For biochemical confirmation, fermentation test of L. acidophilus, L. casei and L. 
plantarum, was prepared and carried out as described by Schreckenberger and Blazevic (1976) 
(17) with modification. Sugars were substituted with sorbitol (Thermo Fisher) and raffinose 
(Fisher Scientific). The tests were incubated aerobically at 37°C with negative controls and the 
results were observed after four to eight hours. A color change from blue to yellow indicated the 
strain was able to utilize the sugar. Lactobacillus acidophilus was confirmed if the sugar test 
with raffinose was positive, but the test was negative for sorbitol (17, 22). A sugar test positive 
with sorbitol and negative with raffinose indicated the presence of L. casei (11, 23).  Both tests 
were positive as an indication of L. plantarum (3, 23).  
 
Species determination 
A Polymerase Chain Reaction (PCR) method was employed to identify the gene 
encoding D-alanine-D-alanine ligase specific for E. faecium (ddl E. faecium) in each DFM. Cell 
suspensions of a few fresh enterococci colonies were prepared in 50 μL of 7.5 Chelex 100 Resin 
(Bio-Rad laboratories, Hercules, California) (16) with slight modifications. The suspension was 
heated for 15 minutes at 100°C in a heating block and centrifuged in a microcentrifuge 
(AccuSpin Micro R Filter Benchtop Centrifuge, Fisher Scientific) at 4032 x g for 1 minute. The 
supernatant liquid was collected and used for the PCR assay.  The primers and PCR conditions 
were based on Kariyama et al., (2000) (9) with some modifications, with the primers designed to 
amplify ddl of 658 bp. A total volume of 25 μL was used in the PCR assay which contained 
reaction components of 2.5 μL 10x PCR Reaction buffer (Invitrogen), 1.5 μL of 25 mM MgCl2 
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(Bullseye, MIDSCI), 2 μL of 1mM dNTP (Takara Clontech), 0.2 μL of 1 unit/25 μL Taq 
polymerase (Bullseye, MIDSCI), 0.5 μL of forward and reverse primers (Integrated DNA 
Technologies) and 2.5 μL of DNA template.  
 The thermal cycling was carried out in an Eppendorf Mastercycler gradient (USA 
Scientific) system: initial denaturation at 94°C for 5 min, followed by 30 cycles of amplification 
of denaturation at 94°C for 60 seconds, then annealing at 54°C for 60 seconds, elongation at 
72°C for 60 seconds, extension at 72°C for 60 seconds and a final extension step at 72°C for 10 
minutes. The positive control used in the assay was E. faecium 7A and the negative control was 
water. The PCR products were then analyzed on 1.5% agarose gel containing ethidium bromide 
(0.5 μg/mL) in 1X Tris-acetate-Ethylenediaminetetraacetic acid (TAE) buffer. The DNA size 
marker used was 1kb (Promega) with 6x Blue/Orange Load Dye (Promega). The gel was viewed 
under ultraviolet (UV) light. Distinct bands were produced, corresponding to their molecular 
sizes. All the isolated strains E. faecium were submitted to the Kansas State Veterinary 
Diagnostic Laboratory to further confirm the identification of the species of each genus using 
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF). 
 
Kirby-Bauer Disk Diffusion   
Antimicrobial susceptibility patterns of each strain were determined using the Kirby-
Bauer Disk Diffusion Antimicrobial Susceptibility Testing (AST) method. Twenty discs from 
various antibiotic classes were purchased from Hardy Diagnostics which including ampicillin, 10 
μg; chloramphenicol, 30 μg; clindamycin, 2 μg; erythromycin, 15 μg; kanamycin, 30 μg; 
tetracycline, 30 μg; vancomyin, 30 μg; ampicillin/sulbactam, 20 μg; ceftriaxone, 5 μg; 
ciprofloxacin, 5 μg; imipenem, 10 μg; levofloxacin, 5 μg; sulfamethoxazole/trimethoprim 25 μg; 
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and tigecycline, 15 μg, and from Becton Dickinson (BD), gentamicin, 120 μg; linezolid, 30 μg; 
synercid (Quinupristin and Dalfopristin), 15 μg; metronidazole, 80 μg; rifampin, 5 μg; and 
streptomycin, 300 μg. Staphylococcus aureus strain ATCC 25923 was used as quality control for 
E. faecium. Each bacterial strain to be tested was grown in appropriate broth overnight and 
adjusted to a 0.5 McFarland standard at 625nm. The bacterial isolates were streaked onto agar 
plates and ten antibiotics were placed on a 150mm plate, with the other ten on another plate. The 
plates were incubated aerobically overnight at 37°C for E. faecium and Bacillus strains.  
Lactobacillus species plates with antibiotics were incubated anaerobically at 37°C and P. 
freudenreichii plates were incubated anaerobically at 30°C. All assays were performed in 
duplicates for three days on Mueller Hinton agar (Becton Dickison, BD) for E. faecium, Bacillus 
(5) and P. freudenreichii strains and MRS agar with 0.25% L-cysteine HCl for Lactobacillus 
strains (10), which was determined to be an optimal media for the enumeration of Lactobacillus 
as there were no guidelines in CLSI to perform Kirby-Bauer Disk Diffusion for Lactobacillus. 
The zone of inhibition was measured across the discs in millimeters (mm). The results were 
interpreted based on CLSI (5) and European Committee on Antimicrobial Susceptibility Testing 
(19, EUCAST) interpretive standards for E. faecium, Bacillus strains and P. freudenreichii. One-
way analysis of variance (ANOVA) and standard deviation were calculated to determine if the 
results in one day were significantly different to the results in three days.  
Broth Microdilution   
Broth microdilution assay was used to further confirm the susceptibility of the strains 
based on the Kirby-Bauer results. The assay was performed according to Clinical and Laboratory 
Standards Institute (CLSI) (5) guidelines in duplicates for three days. E. faecalis strain ATCC 
29212 was used as quality control for E. faecium. Broth microdilution assay was performed in 
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96-well plates for E. faecium, Bacillus species (5) and P. freudenreichii in cation-adjusted 
Mueller-Hinton broth (Becton Dickinson, BD). A blue dye, resazurin, used to quantify bacterial 
content, was added (30 μL) at 0.01% (13) the next day and incubated overnight again. Color 
change from blue to pink indicated resazurin was reduced by E. faecium. This positive result 
indicated bacterial growth (14). The MIC results were determined where color changes were 
prevented by the lowest drug concentration. EUCAST (20) and EFSA (19) breakpoints were 
referred to determine the susceptibility of strains if none were found in CLSI. EFSA guidelines 
recommended performing broth microdilution assay based on CLSI guidelines (5, 19). Both 
CLSI and EFSA did not provide Kirby-Bauer Disk Diffusion interpretive values for 
Lactobacillus, Bacillus spp., and Propionibacterium freudenreichii. Hence, based on the results 
of Disk Diffusion, broth microdilution assay was performed when the strains did not have zone 
of inhibition around the antibiotic and tested against antibiotics they were not intrinsically 
resistant to. Broth microdilution assays for Lactobacillus strains were performed in cation-
adjusted Mueller Hinton broth with 4% lysed horse blood (6), cation-adjusted Mueller Hinton 
broth for Bacillus species, E. faecium (5) and Propionibacterium freudenreichii. For 
Lactobacillus strains, the MIC was determined by measuring the absorbance at 625nm with a 
spectrophotometer. Resazurin was used to observe color change for Bacillus species 
Propionibacterium freudenreichii. Minimum inhibitory concentrations were determined and the 
susceptibility of the strains was interpreted based on the breakpoints in CLSI, EUCAST and 
EFSA (5, 6, 19, 20). MIC50 and MIC90 of E. faecium were calculated, whereby MIC50 was 
taken as the MIC of median value. MIC90 represented the concentration of antibiotic that 
inhibited 90% of the strains tested.  
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DFM second lots 
Our results from Kirby-Bauer Disk Diffusion and broth microdilution from the first lot of 
DFM led us to question if the resistance would vary from different lots produced at a later time 
frame. Questions were also raised regarding the variability of resistance profiles between 
different colonies in a single lot, especially E. faecium. Out of the ten DFMs, three second lots of 
the list of ten DFMs were purchased. Using the same methods, Kirby-Bauer Disk Diffusion and 
broth microdilution assays were performed as described above for each strain in the DFM. The 
results were compared to the first lots for Enterococcus, Lactobacillus and Bacillus strain and 
also between different E. faecium colonies in the second lots. Paired-samples t-test were applied 
using Minitab, using each strain from each product as the experimental unit, to determine 
whether there was a statistically significant mean difference in average diameters over three days 
in strains of the second lot and the strains in the first lot, as well as between E. faecium colonies 
in the second lot.  
 
PCR Assay for antimicrobial resistance genes detection   
A PCR assay was used to detect and quantify AMR genes in E. faecium. The 
antimicrobial genes of interest were ermB, tetM, vanA and vanB. The primers and PCR 
conditions were chosen according to references in Table 2-7, and modified to amplify ermB 
(175bp) (8), tetM (156bp) (8), vanA (1030bp) and vanB (433 bp) (9). The running conditions 
were as follows: initial denaturation of 3 min at 94°C, 36 cycles each of 30s at 94°C, 30s of 
annealing for 30s at 72°C, and a final elongation of 2 min at 72°C using Taq DNA polymerase 
(TaKaRa). The positive control used for ermB and tetM was E. faecium 7A, E. faecalis 
V583PMV158GFP (previously obtained from Dr. Lynn Hancock, Kansas State University) as a 
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positive control for vanB and E. faecium R2-TX-5034 (previously obtained from Dr. Ludek 
Zurek, Kansas State University) as a positive control for vanA. Based on conjugation and whole 
genome sequencing results, further tests were run to determine if other erythromycin resistance 
genes such as ermA and ermC were present in the donors, recipient and transconjugants. Positive 
controls used for ermA was Staphylococcus aureus RN1389 (19) and ermC was Staphylococcus 
aureus RN4220 (19).The two control strains were kindly provided by Dr. Charlene Jackson 
(U.S. National Poultry Research center, Athens, GA).  
 
Spotted DNA Microarray Assay  
A spotted DNA microarray method was used as it is dependable and able to detect 
various resistance genes in a single experiment. The complete array contained 489 70mer oligos 
printed on an Ultra Gap slide (Corning, Lowell, MA) at a concentration of 35 μM in replicates of 
3, 10 or 16. The protocol described by Peterson et. al., 2011 (15) was used and adjusted with 
some modifications. Genomic DNA for microarray was first extracted and labeled with 
BioPrime Plus Array CGH Genomic Labeling System (Invitrogen, Carlsbad, CA). A random 
primer was then incorporated and 1.5 μL of 1 mM Cy3 or Cy5-dCTP was spiked in to increase 
the fluorescence signal. The dye incorporation and amplification were checked using the 
Nanodrop ND-1000 spectrophotometer (Nanodrop-Thermo Fisher Scientific, Wilmington, DE). 
The genomic DNA was mixed with 1 μL of 1 nM stock of Cy3 or Cy5-labeled 25 mer and 2X 
Hybridization solution (GeniSphere, Hatfield, PA). The mixture was heated for 5 minutes at 
80°C and carefully added to the array chips, followed by overnight hybridization. The chips were 
washed for 10 minutes each in the wash buffers 10X SSC + 0.2% sarkosyl, 10X SSC and 0.2X 
SSC. Finally, the slides were quickly dipped in water, centrifuged in a 50 mL Falcon Tube at 
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2,200 x g to spin it dry and the fluorescent hybridization signals were visualized using the 
GenePix 4000B slide reader (Molecular Devices, Sunnyvale, CA) and compared to the GenePix 
Array List (GAL) file created by the microarray slide printer (15). Microarray was used to detect 
resistance genes in three DFMs, one L. acidophilus and one P. freudenreichii strain, and three E. 
faecium strains. The results from the microarray are shown in Tables 2-8-1, 2-8-2 and 2-8-3. 
 
Whole Genome Sequencing    
  Nine E. faecium strains were submitted to the Food and Drug Administration (FDA) for 
detection and data analysis of resistance genes. The results are shown in Table 2-9. 
 
Conjugation Assay   
Donor strains of E. faecium, which were resistant towards erythromycin with an MIC ≥ 8 
μg/mL and susceptible to linezolid, MIC: ≤ 2 μg/mL, were conjugated with a recipient strain, E. 
faecium 45-25, susceptible to erythromycin but resistant to linezolid. The recipient was kindly 
provided by Dr. Ludek Zurek (Kansas State University). The assay was repeated three times. 
Prior to conjugation, donor and recipient strains were streaked on erythromycin and linezolid 
plates of varying concentration to determine the highest concentration both strains were able to 
tolerate. The plates with the concentration 3 μg/mL worked best for both antibiotics. Both donors 
and recipient were grown in Brain Heart Infusion (BHI) broth overnight for 16-18 hours. At 1:5 
dilutions, donor and recipient were mixed together. A filter paper was placed on a BHI agar 
without antibiotics and 1 mL of the mixed culture was pipetted carefully on the filter paper. The 
plate was incubated at 37°C overnight. After 16-18 hours, the filter paper was immersed in 1 mL 
of BHI broth and mixed well. The mixture was plated on BHI plates with erythromycin or 
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linezolid antibiotic plates, and BHI plates with both antibiotics. Transconjugants observed on 
dual antibiotics were streaked onto agars with erythromycin only or linezolid only antibiotics.  
 
Pulse-Field Gel Electrophoresis (PFGE)  
The transconjugants, donors and recipient were subjected to PFGE to observe for genetic 
diversity (1). The standard used in this assay was Salmonella, based on the protocol from CDC 
(4). The PFGE for Enterococcus strains was performed as described by Amachawadi et. al (1). 
Fresh isolates were incubated overnight in 5 mL of BHI broth at 37°C. The next day, 1 mL of 
culture was centrifuged down and resuspended in 200 μL of 0.85% saline solution. Plug molds 
were prepared by mixing 200 μL of 1.6% SeaKem Gold agarose (Lonza, Switzerland) and 200 
μL of bacterial suspension, and allowing the mixture to sit at room temperature for 30 minutes. 
Plugs were transferred into 10 mL of lysis solution (6 mM Tris-HCl, pH 7.4, 1 M NaCl, 100 mM 
ethylenediaminetetraacetic acid [EDTA], 0.5% sodium lauryl sarcosine, 0.5% Brij, 0.2% 
deoxycholate, 500 μg/mL lysozyme and 20 μg/mL RNaseA for 4 hours with gentle shaking at 
37°C. After 4 hours, the lysis solution was transferred to another 50 mL Falcon tube with 10 mL 
of EDTA/sodium dodecyl sulfate (SDS)/Proteinase K (ESP) buffer (10 mM Tris-HCl, pH 7.4, 1 
mM EDTA, 1% SDS and 50 μg/mL Proteinase K) and incubated overnight at 50°C with gentle 
shaking. After overnight incubation, the ESP solution was discarded and washed with Tris-
EDTA (TE) buffer (10 mM Tris-HCl, pH 7.4, 0.1 mM EDTA) for 10 minutes for three separate 
washings at room temperature. The plugs were stored at 4°C until further use. About 1 mm of the 
plugs were placed in 1X Buffer of SmaI restriction enzyme for 10 minutes at room temperature 
and then 4 hours with the 20U of restriction enzyme at 25°C. The plugs were transferred into a 
100 mL of 1% SeaKem Gold agarose agar in 0.5X Tris/Borate/EDTA buffer (TBE) buffer. The 
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agar was placed in an electric field, CHEF-DR II (BioRad, Richmond, CA). The pulse time was 
set as follows: 
Block 1: Initial time 3.5s, final time 25s, 200V for 12 hours 
Block 2: Initial Time 1s, final time 5s, 200V for 8 hours 
After 20 hours, the gel image was captured with Gel Doc 2000 system (BioRad). The band 
patterns were analyzed using BioNumerics software (Applied Maths, Austin, TX). The isolates 
were arranged in groups based on similar banding patterns.  
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Results 
Kirby-Bauer Disk Diffusion Results 
E. faecium  
Nine strains of E. faecium were isolated and identified from the ten DFM.  Six strains 
were determined to be resistant to ceftriaxone. Five strains were resistant and 1 was 
intermediately susceptible to clindamycin, 5 strains were resistant to erythromycin and 4 strains 
were interpreted as intermediately susceptible to erythromycin. One E. faecium strain was 
intermediately susceptible towards synercid, two strains were resistant and 5 strains were 
intermediately susceptible to ciprofloxacin. Results also demonstrated four E. faecium strains 
resistant to trimethoprim/sulfamethoxazole. Eight strains of E. faecium were resistant to 
rifampin. All the strains were resistant towards metronidazole whether incubated aerobically or 
anaerobically. 
 
Lactobacillus 
Six strains of L. acidophilus were isolated. Two strains did not have a zone of inhibition 
to vancomycin. None of the L. acidophilus strains had zone of inhibition for kanamycin, 
metronidazole, or sulfamethoxazole/trimethoprim. Four strains did not have a zone of inhibition 
for levofloxacin and five of them lacked zone of inhibition for ciprofloxacin. From the four 
strains of L. casei isolated from four DFM, none had a zone of inhibition zone for kanamycin, 
vancomycin, ciprofloxacin, and metronidazole. Three strains of L. casei did not have zone of 
inhibition for sulfamethoxazole/trimethoprim. Two strains of L. plantarum did not demonstrate 
any zone of inhibition for kanamycin, vancomycin, ciprofloxacin and metronidazole. One of the 
two strains showed the same characteristic for sulfamethoxazole/trimethoprim.  
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Bacillus    
Two strains of B. subtilis showed no zone of inhibition for both clindamycin and 
erythromycin in two DFMs. A strain of Bacillus pumulis did not have a zone of inhibition for 
metronidazole.  
 
P. freudenreichii   
This strain was susceptible to all antibiotics tested except it did not have a zone of 
inhibition for kanamycin and levofloxacin.     
 
A one-way ANOVA was conducted to determine if there was a difference in the Kirby-Bauer 
results for one day and for three days for all the strains. At a 99% confidence interval, there was 
no statistically significant difference between the two groups as determined by a one-way 
ANOVA, p > 0.01. 
 
MIC results  
E. faecium  
Six strains of E. faecium were determined to be resistant to ceftriaxone, MIC ≥ 0.25 
μg/mL. Five out of nine strains were resistant to erythromycin, MIC ≥ 8 μg/mL, and four were 
interpreted as intermediately susceptible to the same antibiotic (MIC50 and MIC90: 8 μg/mL). 
All E. faecium strains demonstrated resistance to clindamycin, MIC > 0.5 μg/mL (MIC50 and 
MIC90: 8 μg/mL). MIC results also showed that only 2 strains were resistant to ciprofloxacin, 
MIC ≥ 4 μg/mL (MIC50: 1 μg/mL; MIC90: 8 μg/mL) and 8 strains were resistant towards 
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rifampin, MIC > 4 μg/mL, (MIC50: 8 μg/mL; MIC90: 16 μg/mL) All the E. faecium strains were 
resistant to metronidazole, MIC > 32 μg/mL, whether incubated aerobically or anaerobically 
(MIC50 and MIC90: 64 μg/mL). Four strains were resistant to trimethoprim/sulfamethoxazole, 
MIC ≥ 1 μg/mL (MIC50: 0.125 μg/mL; MIC90: 2 μg/mL). 
 
Lactobacillus  
The MIC results confirmed the resistance of two L. acidophilus strains towards 
vancomycin, MIC > 32 μg/mL. All six strains were resistant to metronidazole, MIC > 32 μg/mL. 
Similar results were obtained for L. casei and L. plantarum, where all the strains were 
determined to be resistant to metronidazole, MIC > 32 μg/mL. 
 
Bacillus  
Two strains of B. subtilis were resistant to clindamycin, MIC > 4 μg/mL, and 
erythromycin, MIC > 8 μg/mL. A strain of B. pumulis was resistant to metronidazole, MIC > 32 
μg/mL.  
 
P. freudenreichii  
MIC results confirmed the resistance of this strain to kanamycin, MIC > 64 μg/mL. The 
MIC for levofloxacin was 16 μg/mL.  
 
 Results for second lots of DFMs  
Similar results were observed when comparing the data between the first and second 
DFM lots. A paired-samples t-test was applied and determined there was no statistically 
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significant mean difference in average diameters of the Kirby-Bauer Disk Diffusion results in the 
second and first lots, p > 0.01, at a 99% confidence interval. Using one-way ANOVA, the 
susceptibility of four different colonies of E. faecium in the second lot was similar and was not 
significantly different, p > 0.01.   
 
 PCR Assay Results   
The E. faecium strains tested did not display any of the target resistance genes: ermB, 
tetM, vanA and vanB.  The presence of an erythromycin resistance gene, ermA, was detected in 
the donors, recipient and transconjugants from the conjugation assay. Another erythromycin 
resistance gene, ermC, was not detected in any of the strains.  
 
 Microarray Results  
Tables 2-8-1, 2-8-2 and 2-8-3 show the various resistance genes found in a combination 
of all the strains in three DFMs, E. faecium from three DFMs, and L. acidophilus and P. 
freudenreichii from one DFM.  
 
 Conjugation Results  
Transconjugants were observed after four to five days on dual antibiotics (erythromycin 
and linezolid) plates when two E. faecium donor strains were conjugated with an E. faecium 
recipient strain. The transconjugants also grew on agars with either erythromycin or linezolid 
plates.  
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 PFGE Results 
 Enterococcus faecium transconjugants, donors and recipient were subjected to PFGE to 
observe the genetic relationship between the strains with a homology cut-off value of 90%. 
Antibiogram patterns (Figure 6) did not show distinct similarities between transconjugants and 
donor, but similar patterns were observed between transconjugants and recipient.  
 
Whole-Genome Sequencing Results 
 Data analysis of WGS for nine E. faecium strains reveald the presence of an intrinsic 
erythromycin gene, msrC. Several plasmids were also detected with functions including 
potentially mediating resistance to macrolide, lincosamide and streptogramin B alpha (MLSB) 
antibiotics (pAMbeta1), pGB354 with rate-limiting initiator protein RepR, and bacteriocin-
encoding plasmid pEF1.   
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Discussion Chapter 3 - 
In this study, it has been demonstrated that commercially available DFM products used in 
the U.S. feedlot industry carry various AMR genes. It is consequential to note that there is a 
concern related to transferable resistance by horizontal gene transfer in the gastrointestinal flora, 
with enterococci having an array of genetic versatility and ability to recruit and express 
antimicrobial resistance determinants (3, 12). The E. faecium strains used in these ten products 
did not exhibit vancomycin, tetracycline, linezolid or a combination of quinupristin and 
dalfopristin (synercid) acquired resistance genes, which are of medical importance. Resistance to 
aminoglycosides results from limited drug uptake related to proteins involved in electron 
transport or covalent modification inactivation of the hydroxyl or amino groups of the 
aminoglycoside molecule by naturally occurring enterococcal enzymes. E. faecium has a 
chromosomally encoded 6’-acetyltrasnferase enzyme (AAC(6’)-Ii) able to modify kanamycin 
(12). 
Two E. faecium DFM strains exhibited resistance to ciprofloxacin. A well-described 
mechanism of quinolone resistance is through antibiotic externalization through efflux pumps 
(12). As mentioned previously, rifampin resistance occurs in E. faecium strains, arising from 
various mutations in the rpoB gene encoding the β-subunit of RNA polymerase. This was seen 
in eight of nine E. faecium DFM strains. EUCAST zone diameter interpretive values were used 
instead of CLSI to determine the susceptibility of E. faecium strains to 
trimethoprim/sulfamethoxazole. Generally, enterococci exhibit susceptibility to the compounds 
when tested in vitro. However, four strains were determined to be resistant to those particular 
antibiotics. If tested in in vivo, the compounds are ineffective as enterococci are able to use 
exogenous sources of folate (12). Enterococci are intrinsically resistant to clindamycin, with its 
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resistance mediated by the product of the lsa resistance gene (11) which was observed in all E. 
faecium DFM strains. 
 All the strains demonstrated resistance to metronidazole with no zone of inhibition, 
except P. freudenreichii and B. subtilis strains. This could be due to metronidazole, a synthetic 
antimicrobial agent, being mainly effective against anaerobic bacteria and various protozoans.  
Susceptible microorganisms are affected when intermediates form as a result of the strains’ 
nitroreductase activity, producing a derivative that proceeds to interact with DNA, which can 
cause damage characterized by helix destabilization, strand breakage and concomitant specific 
release of thymidine nucleotides (14). However, despite being incubated anaerobically, 
resistance was still observed in B. pumulis and E. faecium (MIC50 and MIC90: 64 μg/mL) 
strains.  Another study by Delgado et. al. (2005) (6) attributes the resistance towards 
metronidazole (MIC ≥ 32 μg/mL) in lactobacilli due to the absence of hydrogenase activity in 
lactic acid bacteria species. A zone of inhibition was observed for B. subtilis and P. 
freudenreichii to metronidazole. Susceptibility of B. subtilis strains were determined based on 
the interpretive values for Gram-positive anaerobes in CLSI.  
The potential for E. faecium as a donor to transfer resistance to other strains makes the 
resistance profile of this organism in DFM products particularly interesting. As mentioned 
previously, enterococci increasingly cause nosocomial infections, infecting patients with 
unrelated underlying illnesses under antibiotic treatment. This results in serious or life-
threatening infections and the rise of enterococci as a principal clinical challenge for physicians. 
One of the concerning antibiotic resistance characteristics of E. faecium is vancomycin-resistant 
enterococci (VRE), which creates problems for disease management. There have been reports of 
transfer of vancomycin resistance from enterococci to Staphylococcus aureus. Nine DFM strains 
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of E. faecium tested did not exhibit any vancomycin or ampicillin resistance. Ampicillin 
resistance is associated with vancomycin resistance, often being detected before vancomycin 
resistance in E. faecium (13).  
Erythromycin resistance with an MIC at 8 μg/mL was observed in five strains from five 
DFMs. From two DFMs, E. faecium strains showed potential for transfer of erythromycin 
resistance. When plated on agar containing both erythromycin and linezolid at 3 μg/mL, several 
colonies of transconjugants were observed on the plates. Whole genome sequencing revealed the 
presence of msrC, encoding a putative efflux pump of the ABC transporter family, with the 
ability to transfer erythromycin resistance. PCR assay also confirmed the presence of msrC gene 
in the donors, transconjugants and recipient. However, Portillo et. al (2000) (14) reported it was 
an indigenous or intrinsic gene present in E. faecium chromosomes, not an acquired resistance 
due to selective pressure conferring resistance towards macrolides. This intrinsic gene is related 
to msrA and msrB in staphylococci, conferring low-level resistance to streptogramin B 
compounds (7). PFGE results demonstrated similar profiles between transconjugants and 
recipient, confirming that conjugation occurred. However, ermA was detected by PCR assay in 
the E. faecium donors, transconjugants and recipient, which were not identified by WGS. 
Based on initial AST results, a question was raised if the antimicrobial resistance profiles 
for the lots following after would have a variation in susceptibility profiles. Comparing to the 
first lots, the results of the second lots of three DFMs (E. faecium, L. acidophilus, L. casei and L. 
plantarum) were similar and not significantly different. 
Microarray was used to screen various genetic information and to detect many genes 
harbored by bacteria in a single assay. Compared to traditional PCR, the advantage of using this 
assay was that target genes were identified based on its internal sequences and not on the length 
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of the PCR products, with the oligonucleotides probes having greater specificity than PCR 
primers. Two erythromycin resistance genes, ermB and ereA, resistance genes were detected in 
E. faecium strains from two DFM. Although it was determined that both strains were resistant 
towards erythromycin, the presence of ermB was not verified through PCR amplification. 
Enterococcus faecium strains were positive for some genes but susceptible to a corresponding 
antibiotic. For example, tetracycline resistance genes were detected in a strain susceptible to that 
antibiotic. This could be due to high numbers of false positives causing lower specificity and 
predictive values of a positive test. This demonstrated weak correlation with the resistance 
phenotypes (1). However, it was also possible that the genes were nonfunctional due to 
mutations or open reading frames (ORFs).  
Tests were recommended to be performed and results interpreted according to CLSI as it 
is an internationally recognized standard (17). However, not all strains have interpretive values, 
especially fastidious bacteria. Lactobacillus and Bacillus only had breakpoint and cut-off values 
for certain antibiotics to determine their MIC. Propionibacterium did not have susceptibility 
interpretive values for Kirby-Bauer disk diffusion and broth microdilution in CLSI as there were 
no adequate studies to develop reproducible, definitive standards for results interpretation (5). In 
the absence of CLSI breakpoints, the epidemiological cut-off values in EFSA were used. The 
term “breakpoint” has been used in various ways including referring to the MIC for antimicrobial 
distinguishing populations of bacteria with acquired or selected resistance mechanisms from the 
wild-type strains which does not harbor selected or acquired resistance to an examined 
antimicrobial or others with the same mechanism/site of action. Clinical breakpoints (CLSI) refer 
to MIC concentrations separating strains where there is a possibility of treatment success from 
the bacteria where treatment is more likely to fail. These breakpoints are derived from 
49 
prospective human clinical studies where the outcomes are compared to the MICs of the 
infecting pathogen. The term “epidemiological, or wild-type, (EFSA) cutoff value has been 
proposed by the European Committee on Antimicrobial Susceptibility Testing in an attempt to 
decrease confusion regarding the meaning of the term “breakpoint” (19). Breakpoints are 
necessary to categorize organisms into susceptible, intermediately susceptible, and resistant for 
the antimicrobial agent. This requires understanding of dosing, pharmacokinetics, 
pharmacodynamics, clinical outcome in clinical situations, and MIC organism distributions 
without resistance mechanisms. (9). Breakpoints also allow communication from the clinical 
laboratory to the prescriber in regards to possibility that a particular antimicrobial regimen will 
be clinically useful to treat patients with infections (17). Other breakpoints used when CLSI 
values are not available, is the European Committee on Antibiotic Susceptibility Testing 
(EUCAST) clinical breakpoints. These breakpoints are based on pharmacokinetic-
pharmacodynamic (PK-PD) properties, epidemiological MIC cut-offs (ECOFFS) and in part, the 
data from clinical outcomes (8, 10). EUCAST guidelines are more freely available and a study 
by Kassim et.al (2016) showed an acceptable level of agreement between the CLSI AST 
guidelines and EUCAST, specifically E. coli, S. aureus and P. aeruginosa (10). However, 
discrepancies have been observed due to different epidemiologies, a lower number of data points 
in the EUCAST distribution, bias resulting from low number of laboratories contributing data, 
pooling of results from various sources and differences from ECOFF determination methods. 
Hombach et. al (2014) reported the importance of determining clinical breakpoints (8). Reliable 
clinical breakpoints/ECOFFs require species-specific criteria. Antibiotic disk content is also 
critical to separate resistant from wild-type populations and diameter distributions are also 
influenced by pooling of data from various sources (8). 
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With that being said, there is a need for better standardized breakpoints to indicate and 
confirm these strains’ susceptibility for future references. 
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Conclusion  
In the increasing development of antimicrobial resistance, the gut plays an important role 
and is the center of AMR (2). Alterations in the gut microbiome occur through ingestion of 
antibiotics, highly pathogenic microorganisms, or just aggressive non-pathogenic colonizers 
which may or may not carry transferable resistance genes. The presence of possible transfers of 
resistance genes comprise of a theoretical risk of transfer to less pathogenic organisms in gut 
microbial community (16). This study has provided results for some of the strains used in DFM 
that are considered safe and why there is a need for resistance profiles for them including 
organisms considered as safe like Lactobacillus and Bifidobacterium species (16). DFM strains 
used in commercial products in the industry must be evaluated to make sure that there are no 
transferable resistance genes before going out to the market. Using low cost genomic sequencing 
technologies to confirm the absence of genes of concern is advisable (16). Established, better 
interpretive criteria and standardized guidelines are necessary for performing tests to determine 
the resistance and susceptibility of these strains, especially for lactic-acid bacteria.  
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Figures and Tables used in Chapter 2 Chapter 4 - 
Table 2-1 Strains in ten DFM used in this study 
Strains Number of strains 
Enterococcus faecium 9 
Lactobacillus acidophilus 6 
Lactobacillus casei 4 
Lactobacillus plantarum 2 
Bacillus subtilis 3 
Bacillus pumulis 1 
Propionibacterium freudenreichii 1 
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Table 2-2 List of antibiotics and zone diffusion disc contents used in this study 
 
Antimicrobial Agent Concentration (μg) 
Ampicillin/ Sulbactam 20 
Ampicillin 10 
Ceftriaxone 30 
Chloramphenicol 30 
Ciprofloxacin 5 
Clindamycin 5 
Erythromycin 15 
Gentamicin 120 
Imipenem 10 
Kanamycin 30 
Levofloxacin 5 
Metronidazole 80 
Rifampin 5 
Streptomycin 300 
Sulfamethoxazole/Trimethoprim 25 
Synercid (Quinuprisitn/Dalfopristin) 15 
Tetracycline 30 
Tigecycline 15 
Vancomycin 30 
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Table 2-3-1 Disk Diffusion: Enterococcus faecium  
  
n.a.: not available 
n: number of strains; S: susceptible; I: Intermediately susceptible; R: Resistant 
CLSI*: Zone Diameter Interpretive values from Streptococcus species β –Hemolytic Group  
EUCAST*: Zone Diameter breakpoint from Streptococcus groups A, B, C and G  
 
 
 
 
  
Antimicrobial 
Agent 
Averages 
(mm) for nine 
strains 
Ranges for 
nine strains 
Quality 
Control 
Ranges 
Susceptible/Intermediate/ 
Resistant Strains 
Guidelines 
followed 
Ampicillin 25.94 21-30 27-35 S ≥ 15 (n= 9) CLSI 
Amp/Sul 27.61 24-32 29-37 S ≥ 15 (n= 9) CLSI 
Ceftriaxone 11.45 0-24 22-28 S ≥ 18 (n= 3) 
 R < 18 (n= 6) 
EUCAST* 
Chloramphenicol 22.68 20-25 4-16 S ≥ 18 (n= 9) CLSI 
Ciprofloxacin 19.25 13-26 22-30 S ≥ 21 (n= 2) 
I, 16-20 (n= 5) 
 R ≤ 15 (n= 2) 
CLSI 
Clindamycin 15.88 8-33 24-30 S ≥ 19 (n= 3) 
 I, 16-18 (n= 1) 
 R ≤ 15 (n= 5) 
CLSI* 
Erythromycin 14.93 11-21 22-30 I, 14-22 (n= 4) 
 R ≤ 13 (n= 5) 
CLSI 
Gentamicin 22.67 20-28 19-27 S ≥ 10 (n= 9) CLSI 
Imipenem 26.38 23-30 n.a. S ≥ 21 (n= 9) EUCAST 
Kanamycin 4.29 0-14 19-26 n.a. n.a. 
Levofloxacin 18.82 17-24 25-30 S ≥ 17 (n= 9) CLSI 
Linezolid 25.60 22-30 25-32 S ≥ 23 (n= 9) CLSI 
Metronidazole 0 0 n.a. n.a. n.a. 
Rifampin 13.69 11-27 26-34 S ≥ 20 (n= 1) 
 R ≤ 16 (n= 8) 
CLSI 
Streptomycin 20.59 18-24 14-22 S ≥ 10 (n= 9) CLSI 
Synercid 21.59 17-27 21-28 I, 16-18 (n= 1) 
 S ≥ 19 (n= 8) 
CLSI 
Tetracycline 26.46 22-32 24-30 S ≥ 19 (n= 9) CLSI 
Tigecycline 23.21 17-28 20-25 S ≥ 18 (n= 9) EUCAST 
Trim/Sulfa  26.48 20-31 24-32 R ≤ 21 (n= 4) EUCAST 
Vancomycin 20.09 18-22 17-21 S ≥ 17 (n= 9) CLSI 
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Table2-3-2 Disk Diffusion: Lactobacillus acidophilus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: No interpretive values found for Lactobacillus acidophilus 
n.a.: not available 
n: number of strains 
 
 
 
  
Antimicrobial Agent Averages (mm) for 
six strains 
Ranges for 
six strains 
Quality 
Control 
Ranges 
Absence of 
Zone of 
Inhibition 
Ampicillin 32.56 28-37 30-36 n=0 
Amp/Sul 34.10 32-38 n.a. n=0 
Ceftriaxone 30.44 22-34 30-35 n=0 
Chloramphenicol 28.76 27-31 23-27 n=0 
Ciprofloxacin 2.54 0-16 n.a. n=5 
Clindamycin 21.49 9-40 19-25 n=0 
Erythromycin 28.96 22-34 25-30 n=0 
Gentamicin 19.67 15-28 n.a. n=0 
Imipenem 30.35 22-39 n.a n=0 
Kanamycin 0 0 n.a. n=6 
Levofloxacin 4.82 0-17 20-25 n=5 
Linezolid 32 28-37 25-34 n=0 
Metronidazole 0 0 n.a. n=6 
Rifampin 27.63 21-33 25-30 n=0 
Streptomycin 19.93 0-29 n.a. n=1 
Synercid 23.81 18-31 0.25-1 n=0 
Tetracycline 27.74 13-34 27-31 n=0 
Tigecycline 27.45 20-32 23-29 n=0 
Trim/Sulfa  0 0 20-28 n=6 
Vancomycin 12.29 0-28 20-27 n=2 
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Table 2-3-3 Disk Diffusion: Lactobacillus casei  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: No interpretive values found for Lactobacillus casei 
n.a.: not available 
n: number of strains 
 
 
 
 
 
 
 
 
 
  
Antimicrobial Agent Averages (mm) for 
four strains 
Ranges for 
four strains 
Quality 
Control 
Ranges 
Absence of 
Zone of 
Inhibition 
Ampicillin 34.42 28-39 30-36 n=0 
Amp/Sul 35.27 31-42 n.a. n=0 
Ceftriaxone 28.46 23-33 30-35 n=0 
Chloramphenicol 26.71 26-27 23-27 n=0 
Ciprofloxacin 0 0 n.a. n=4 
Clindamycin 25.65 23-29 19-25 n=0 
Erythromycin 27 23-30 25-30 n=0 
Gentamicin 17.59 15-21 n.a. n=0 
Imipenem 26.67 21-38 n.a n=0 
Kanamycin 0 0 n.a. n=4 
Levofloxacin 11.29 0-17 20-25 n=1 
Linezolid 31.67 28-35 25-34 n=0 
Metronidazole 0 0 n.a. n=4 
Rifampin 28.48 24-31 25-30 n=0 
Streptomycin 18.54 12-28 n.a. n=1 
Synercid 27.13 26-30 0.25-1 n=0 
Tetracycline 28.71 12-28 27-31 n=0 
Tigecycline 29.19 22-34 23-29 n=0 
Trim/Sulfa  3.125 0-13 20-28 n=3 
Vancomycin 0 0 20-27 n=4 
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Table 2-3-4 Disk Diffusion: Lactobacillus plantarum  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: No interpretive values found for Lactobacillus plantarum 
n.a.: not available 
n: number of strains 
 
 
 
 
 
 
 
 
 
Antimicrobial Agent Averages (mm) for 
two strains 
Ranges for 
two strains 
Quality 
Control 
Ranges 
Absence of 
Zone of 
Inhibition 
Ampicillin 38.92 36-42 30-36 n=0 
Amp/Sul 42.09 41-44 n.a. n=0 
Ceftriaxone 35.5 31-40 30-35 n=0 
Chloramphenicol 28.67 26-31 23-27 n=0 
Ciprofloxacin 0 0 n.a. n=2 
Clindamycin 18.88 10-28 19-25 n=0 
Erythromycin 27.92 24-26 25-30 n=0 
Gentamicin 18.67 16-21 n.a. n=0 
Imipenem 36.75 34-39 n.a n=0 
Kanamycin 0 0 n.a. n=2 
Levofloxacin 3.84 0-8 20-25 n=1 
Linezolid 32.08 29-35 25-34 n=0 
Metronidazole 0 0 n.a. n=2 
Rifampin 23.83 22-26 25-30 n=0 
Streptomycin 13.5 11-16 n.a. n=1 
Synercid 23.83 21-27 0.25-1 n=0 
Tetracycline 27 24-30 27-31 n=0 
Tigecycline 24.25 23-25 23-29 n=0 
Trim/Sulfa  11.59 0-24 20-28 n=1 
Vancomycin 0 0 20-27 n=2 
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Table 2-3-5 Disk Diffusion: Bacillus species 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: No interpretive values found for Bacillus species 
n: number of strains 
 
 
 
 
 
 
  
Antimicrobial Agent Averages (mm) for 
four strains 
Ranges for 
four strains 
Absence of 
Zone of 
Inhibition 
Ampicillin 23.21 18-30 n=0 
Amp/Sul 28.73 26-35 n=0 
Ceftriaxone 20.98 12-30 n=0 
Chloramphenicol 20.29 13-30 n=0 
Ciprofloxacin 31.96 24-37 n=0 
Clindamycin 9.19 0-24 n=2 
Erythromycin 13.67 0-31 n=2 
Gentamicin 33.54 24-40 n=0 
Imipenem 43.83 32-46 n=0 
Kanamycin 27.46 22-32 n=0 
Levofloxacin 33.17 28-39 n=0 
Linezolid 34.23 25-39 n=0 
Metronidazole 12.21 0-21 n=1 
Rifampin 21.46 18-24 n=0 
Streptomycin 30.29 23-37 n=0 
Synercid 17.63 15-21 n=0 
Tetracycline 23.63 21-32 n=0 
Tigecycline 25.65 18-29 n=0 
Trim/Sulfa  35.40 32-39 n=0 
Vancomycin 22.58 21-24 n=0 
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Table 2-3-6 Disk Diffusion: Propionibacterium freudenreichii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: No interpretive values found for Propionibacterium freudenreichii 
n: number of strains 
  
Antimicrobial Agent Averages (mm) Absence of Zone of Inhibition 
Ampicillin 50.67 n=0 
Amp/Sul 57 n=0 
Ceftriaxone 12 n=0 
Chloramphenicol 54.17 n=0 
Ciprofloxacin 67.83 n=0 
Clindamycin 42.67 n=0 
Erythromycin 48.33 n=0 
Gentamicin 43.83 n=0 
Imipenem 36.17 n=0 
Kanamycin 0 n=1 
Levofloxacin 0 n=1 
Linezolid 36.83 n=0 
Metronidazole 56 n=0 
Rifampin 55.67 n=0 
Streptomycin 49.67 n=0 
Synercid 51.33 n=0 
Tetracycline 53.33 n=0 
Tigecycline 45.5 n=0 
Trim/Sulfa  57 n=0 
Vancomycin 59 n=0 
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Table 2-4-1 MIC: Enterococcus faecium  
 
n.a.: not available 
n: number of strains; S: susceptible; I: Intermediately susceptible; R: Resistant 
EUCAST*: MIC breakpoint values from Streptococcus groups A, B, C and G 
 
 
 
 
 
 
 
 
 
 
  
Antimicrobial 
Agent 
Averages 
(μg/mL) 
for nine 
strains 
Ranges 
for nine 
strains 
Quality 
Control 
Ranges 
Susceptible/ 
Intermediate/ 
Resistant Strains 
MIC 
Breakpoints/
Cut-off 
Values 
(μg/mL) 
 Guidelines 
followed 
Ceftriaxone 0.7 0-2 n.a. S ≤ 0.25 (n= 3) 
 R ≥ 0.25 (n= 6) 
0.25  EUCAST* 
Ciprofloxacin 2.5 0.5-8 0.25-2 S ≤ 1 (n= 7) 
 R ≥ 4 (n= 2) 
4  CLSI 
Clindamycin 8.67 2-16 4-16 R >  0.5 (n= 9) 0.5  CLSI* 
Erythromycin 5.67 2-8 1-4 I, 1-4 (n= 4) 
 R ≥ 8 (n= 5) 
8  CLSI 
Metronidazole 32 32 n.a. R > 32 (n=9) 32  n.a. 
Rifampin 12.67 2-16 0.5-4 S ≤ 1 (n= 1) 
 R ≥ 4 (n= 8) 
4  CLSI 
Synercid 0.5 0.5 2-8 S ≤ 1 (n= 9) 4  CLSI 
Trim/Sulfa  0.125 0.125-2 n.a. S ≤ 0.03 (n=5) 
R > 1 (n= 4) 
1  EUCAST 
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Table 2-4-2 MIC: Lactobacillus species 
Lactobacillus acidophilus 
 
**: Indicating breakpoint interpreted based on Gram-positive Anaerobes’ values 
 
Lactobacillus casei 
 
**: Indicating breakpoint interpreted based on Gram-positive Anaerobes’ values 
 
Lactobacillus plantarum 
 
**: Indicating breakpoint interpreted based on Gram-positive Anaerobes’ values 
  
Antimicrobial 
Agent 
Averages 
(μg/mL) 
for six 
strains 
Ranges 
for six 
strains 
Quality 
Control 
Ranges 
Susceptible/ 
Intermediate/ 
Resistant Strains 
MIC 
Breakpoints/
Cut-off 
Values 
(μg/mL) 
 Guidelines 
followed 
Vancomycin 11 0.5-32 0.12-0.5 S ≤ 4 (n= 4) 
 R ≥ 32 (n= 2) 
32  CLSI 
Metronidazole 32 32 0-32 R ≥ 32 (n= 6) 32  CLSI** 
Antimicrobial 
Agent 
Averages 
(μg/mL) 
for six 
strains 
Ranges 
for six 
strains 
Quality 
Control 
Ranges 
Susceptible/ 
Intermediate/ 
Resistant Strains 
MIC 
Breakpoints/
Cut-off 
Values 
(μg/mL) 
 Guidelines 
followed 
Metronidazole 32 32 0-32 R ≥ 32 (n= 4) 32  CLSI** 
Antimicrobial 
Agent 
Averages 
(μg/mL) 
for six 
strains 
Ranges 
for six 
strains 
Quality 
Control 
Ranges 
Susceptible/ 
Intermediate/ 
Resistant Strains 
MIC 
Breakpoints/
Cut-off 
Values 
(μg/mL) 
 Guidelines 
followed 
Metronidazole 32 32 0-32 R ≥ 32 (n= 2) 32  CLSI** 
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Table 2-4-3 MIC: Bacillus species 
 
**: Indicating breakpoint interpreted based on Gram-positive Anaerobes’ values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial 
Agent 
Averages 
(μg/mL) 
for six 
strains 
Ranges 
for six 
strains 
Quality 
Control 
Ranges 
Susceptible/ 
Intermediate/ 
Resistant Strains 
MIC 
Breakpoints/
Cut-off 
Values 
(μg/mL) 
 Guidelines 
followed 
Clindamycin 1.13 0.25-2 0.06-
0.25 
S ≤ 0.25 (n= 4) 
 R ≥ 0.25 (n= 2) 
4  EFSA 
Erythromycin 4.125 0.25-8 0.25-1 S ≤ 0.5 (n= 4) 
R ≥ 8 (n= 6) 
8  CLSI 
Metronidazole 14 8-32 0-32 R ≥ 32 (n= 6) 32  CLSI** 
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Table 2-4-4  MIC: Propionibacterium freudenreichii 
 
 
 
 
 
 
 
 
 
n.a.: not available  
Antimicrobial 
Agent 
Averages 
(μg/mL)  
Ranges 
for six 
strains 
Susceptible/ 
Intermediate/ 
Resistant Strains 
MIC 
Breakpoints/
Cut-off 
Values 
(μg/mL) 
 Guidelines 
followed 
Kanamycin 128 0.25-2 R ≥ 64 (n= 1) 32  EFSA 
Levofloxacin 4.125 0.25-8 n.a. n.a.  n.a. 
67 
 
Table 2-5 Overall MIC Breakpoints/Cut-off Values based on CLSI or EFSA 
 
Antimicrobial 
Agent 
Bacillus 
(μg/mL) 
Enterococcus faecium 
(μg/mL) 
Lactobacillus 
(μg/mL) 
Propionibacterium 
(μg/mL) 
Ampicillin 0.5 16 2** 2** 
Amp/Sul n.a. 16 32/16** 32/16** 
Ceftriaxone 64 0.25* 64** 64** 
Chloramphenicol 8 
32 32** 32** 
Ciprofloxacin 4 4 n.a. n.a. 
Clindamycin n.a. 0.5 4 8** 
Erythromycin 8 8 8 0.5 
Gentamicin 16 > 500 16 n.a. 
Imipenem n.a. 8 16** 8** 
Kanamycin 8 n.a. 16 64 
Levofloxacin n.a. 8 n.a. n.a. 
Linezolid n.a. 8 n.a. n.a. 
Metronidazole 32** 32** 32** 32** 
Rifampin n.a. 4 n.a. n.a. 
Streptomycin 8 > 1000 16 64 
Synercid n.a. 4 n.a. n.a. 
Tetracycline 8 16 16** 16** 
Tigecycline n.a. 0.5 n.a. n.a. 
Trim/Sulfa  n.a. n.a. n.a. n.a. 
Vancomycin 4 32 32 2** 
n.a.: not available 
*: Indicating breakpoint values interpreted based on Streptococcus groups A, B, C and G 
**: Indicating breakpoint values interpreted based on Gram-positive Anaerobes’ values 
  
 
 
 
 
  
European Committee on Antimicrobial Susceptibility Testing 
Clinical and Laboratory Standards Institute (CLSI) 
European Food Safety Authority (EFSA) 
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Table 2-6 MIC50 and MIC90 of E. faecium strains from ten DFMs 
 
Antimicrobial 
Agent 
MIC range 
(μg/mL) 
MIC50  
(μg/mL) 
MIC90 (μg/mL) Breakpoints 
(μg/mL) 
Ceftriaxone 0-2 1 1 0.25* 
Ciprofloxacin 0.5-8 1 8 4 
Clindamycin 2-32 8 8 0.5* 
Erythromycin 2-8 8 8 8 
Metronidazole 16-64 64 64 n.a. 
Rifampin  2-32 8 16 4 
Trim/Sulfa 0.125-2 0.125 2 1* 
* Based on EUCAST 
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Table 2-7 Primers used in antibiotic resistance in E. faecium 
Primers Sequences Annealing 
Temperatures, 
°C 
Product  
Sizes, bp 
References 
ermA F 5’ TCTAAAAAGCATGTAAAAGAA 3’ 
R 5’ CTTCGATAGTTTATTAATATTAGT 3’ 
 
47 645 Sutcliffe et. al, 
1996 
ermB F 5’ GAATCCTTCTTCAACAATCA 3’ 
R 5'ACTGAACATTCGTGTCACTT  3' 
54 175 Modified 
from Jacob et. 
al, 2014 
ermC F 5’ TCAAAACATAATATAGATAAA 3’ 
R 5’ CTTCGATAGTTTATTAATATTAGT 3’ 
47 642 Sutcliffe et. al, 
1996 
tetM F 5′ CTGTTGAACCGAGTAAACCT 3′ 
R 5′ GCACTAATCACTTCCATTTG 3′ 
48 156 Modified 
from Jacob et. 
al, 2014 
vanA F 5’CATGAATAGAATAAAAGTTGCAATA 3’ 
R 5’CCCCTTTAACGCTAATACGATCAA 3’ 
54 1030 Modified 
from 
Kariyama et. 
al, 2000  
vanB F 5’ GTGACAAACCGGAGGCGAGGA 3’ 
R 5’ CCGCCATCCTCCTGCAAAAAA 3’ 
54 433 Kariyama et. 
al, 2000 
F: Forward primer 
R: Reverse primer 
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Table 2-8-1Microarray Result 
Resistance genes detected in three DFM combinations 
DFM Combinations DFM B DFM C DFM F 
Antimicrobial Resistance 
   
Tetracycline tetM       
tet32       
otrA       
tet38       
Trimethoprim dhfrIX       
Virginiamycin vgbA       
Miscellaneous AMR       
Aminoglycosides aadE       
aphA-3       
Glycopeptides vanY A       
Metal Resistance       
Arsenic arsR       
Cobalt/Nickel cnrB       
Copper copB       
Copper/Silver cusA       
Miscellaneous Genes       
Class I Integrons Intl 1 2       
Insertional Elements M13       
DFM B, C and F corresponds to the DFM products in our system 
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Table 2-8-2 Microarray Result 
Resistance genes detected in E. faecium from three DFM 
Enterococcus faecium in DFM DFM C DFM D DFM F 
Antimicrobial Resistance 
   
Chloramphenicol flo*       
Erythromycin ere(A2)       
ermB       
Tetracycline tetC       
tetD       
tetK       
tetV       
tet31       
tet39       
otrA       
Virginiamycin vgbB       
Miscellaneous AMR 
   
Aminoglycosides aadA1       
ANT4-Ia       
Macrolides mphBM       
Metal Resistance 
   
Aluminum ybaX       
Cadmium cadD4       
Cobalt/Nickel cnrB       
Copper cutA       
pcoA       
pcoB       
pcoD       
pcoE       
pcoR       
pcoS       
Copper/Silver cusA       
Metal Genes        
Nickel ncrC       
Silver silA       
silS       
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Transferable Copper tcrZ       
DFM C, D and F corresponds to the DFM products in our system 
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Table 2-8-3 Microarray Result 
Resistance genes detected from other genera 
Strains in a DFM L. acidophilus  P. freudenreichii  
Antimicrobial Resistance      
Tetracycline tetC     
otrC     
otrA     
tetW     
tet(R)     
Trimethoprim dhfrIX     
Virginiamycin vgbB     
Miscellaneous AMR     
Aminoglycosides AAC6-Ii     
Metal Resistance      
Cobalt/Nickel cnrB     
Copper copB     
Copper/Silver cusA     
  cusS     
Metal Genes      
Copper/Zinc/Cadmium czcA 2 copABCD     
Lead pbrA     
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Table 2-9 Whole-Genome Sequencing Results for E. faecium 
 
E. faecium in different DFM Number 
of 
Strains 
 
Antimicrobial 
Resistance 
Group 
  
 
 
Macrolide 
  
 
 
msrC 
  
 
 
9 
 
 
 
 
 
Plasmids 
 
 
 
 
 
Query ID 
pAMbeta1, AF007787 4 
pBT233, X64695 4 
pGB354, U83488 4 
orf17, NC011140 4 
pRE25, X92945 4 
pTEF1, AE016833 4 
p200B, AB158402 4 
E.faeciumContig1183, JDOE 2 
pEF1, DQ198088 2 
E.faeciumContig1258, JDOE 2 
E.faecium287, NZAAAK010000287 2 
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                 Note: DFM A, B and C denotes different E. faecium strains from different DFM products 
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                     Note: DFM A, B and C denotes different L. acidophilus strains different DFM products 
 
  
77 
Figure 3 Comparison of L. casei second to first DFM lot 
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Figure 4 Comparison of L. plantarum second to first DFM lot 
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Figure 5 Comparison of Bacillus subtilis second to first DFM lot 
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Figure 6 PFGE Antibiogram Patterns  
 
 
 
 
 
 
 
 
 
 
 Note:  A and E: Different colonies from the same DFM; C and  D: Different colonies from the same DFM 
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